Sponsored research agreement

Sponsored research agreements (SRAs) sit between unrestricted gifts and pure for-fee service contracts. Standard terms address: scope of work; period of performance; budget and payment schedule; intellectual property (background IP, foreground IP, options to license); publication rights (sponsor review period typically 30 to 90 days, no veto); confidentiality; indemnification; and reporting. Industry SRAs are negotiated through tech-transfer or research contracts offices. Foundation SRAs are often simpler. Misaligned SRA terms (especially IP and publication) are a common friction point.

SRA vs. grant vs. gift vs. MTA/CDA

An SRA is a bilateral contract in which the sponsor typically defines a scope of work and retains contractual remedies if the institution doesn’t perform it — structurally different from a grant, which funds a PI-defined research program under the funder’s general terms without a deliverable-specific contractual scope, and different again from a gift or philanthropic donation, which carries no defined scope of work, no deliverables, and (usually) no IP claim, and is routed through advancement/development rather than sponsored programs. An SRA is also broader in scope than a Material Transfer Agreement (MTA) or confidentiality/non-disclosure agreement (CDA/NDA): those are narrower, single-purpose instruments — transferring one material, or protecting one specific exchange of confidential information — and are frequently executed underneath an SRA to cover individual exchanges within the larger sponsored project, rather than governing the funded project as a whole.

Key negotiated terms

• IP ownership and licensing — background IP (each party’s pre-existing IP) is rarely contested; foreground IP (created during the funded project) is the most heavily negotiated clause. Sponsors typically want assignment or an exclusive option to license; universities typically prefer to retain ownership and grant a license instead.
• Publication rights and delay clauses — see below; usually the single hardest clause to close.
• Indemnification — allocates liability for claims arising from the research or from the sponsor’s use of results. University policy commonly caps, or resists, broad or uncapped indemnification of the sponsor as inconsistent with public/nonprofit institutional risk policy.
• Confidentiality — defines what sponsor-disclosed information the institution must protect and for how long, often layered on top of a standalone CDA/NDA covering pre-agreement discussions.
• Budget and payment terms — milestone- or invoice-based payment schedule, allowable-cost basis, and the institution’s negotiated facilities-and-administrative (F&A/indirect cost) rate; industry sponsors sometimes push back on paying the full federally negotiated rate, a separate negotiation point distinct from the rules governing federal-award F&A recovery.

Publication-delay clauses: the classic sticking point

A university’s core institutional interest is the right to publish; a sponsor’s core commercial interest is protecting patentable or competitively sensitive results before public disclosure. The standard resolution is a short confidentiality-review period (commonly around 30–60 days) letting the sponsor review a manuscript before submission, plus a further period (commonly 30–90 days) if the sponsor needs that time to file a patent application on results disclosed in the manuscript — with most university publication policies capping total delay at roughly 90–180 days and prohibiting indefinite suppression or an outright sponsor veto over content (the sponsor may request removal of its own confidential information, not block the underlying scientific conclusions). A draft clause with no hard cap, or that gives the sponsor a right to prevent publication rather than only delay it, is one of the most common reasons a research contracts office sends an SRA back for revision.

Who signs

An SRA is executed by an institutional official with contracting authority — typically the sponsored programs, research contracts, or technology transfer office — not by the individual principal investigator, even though the PI leads scope-of-work negotiation and is named in the agreement. This matters structurally: the SRA binds the institution (not the individual researcher) to its IP, publication, indemnification, and payment terms, so it is institutional signature authority that makes those terms enforceable.

Standing agreements for recurring sponsors

Where a sponsor relationship recurs — several projects a year with the same company — institutions increasingly negotiate a master or framework research agreement (MRA, sometimes called a blanket or umbrella agreement) once, fixing the IP, publication, confidentiality, and indemnification terms for the relationship as a whole. Individual subsequent projects then need only a short work order or task order incorporating the MRA by reference, avoiding a full renegotiation each time.

References

• AUTM Sponsored Research Agreement Toolkit; UIDP Contract Accord 6, “Foreground Intellectual Property”; NCURA contracts guidance.

Related: Technology Transfer & Innovation · Material Transfer Agreement (MTA) · CRADA · Collaborative Research Agreement (CRA) · Industry-University Research Partnerships · NDAs in Research and Technology Transfer.